A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension associate with left heart disease (PH-LHD) by right heart catheterization.

NCT Number	NCT05824923
Lead Sponsor	Pulnovo Medical (Wuxi) Co., Ltd. Collaborators: The General Hospital of Northern Theater Command, The First Affiliated Hospital with Nanjing Medical University, First Hospital of Tsinghua University, Cangzhou Central Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Shanxi Cardiovascular Hospital, RenJi Hospital, Shanghai 10th People's Hospital, Beijing Anzhen Hospital, West China Hospital, Sichuan Academy of Medical Sciences, The First Affiliated Hospital of Soochow University, TEDA International Cardiovascular Hospital, Tianjin Medical University General Hospital, Renmin Hospital of Wuhan University, Zhongnan Hospital, First Affiliated Hospital Xi'an Jiaotong University, Xiamen Cardiovascular Hospital, Xiamen University, First Affiliated Hospital of Zhejiang University, Shengjing Hospital, First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Gansu Provincial Hospital, Yan'an Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Chongqing Medical University, Huaihe Hospital of Henan University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The First Affiliated Hospital of Nanchang University, Hunan Provincial People's Hospital, Tianjin Medical University Second Hospital, First Affiliated Hospital, Sun Yat-Sen University, The First Hospital of Jilin University
Conditions	Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Enrollment	264 participants
Start Date	2023-08-14
Primary Completion	2025-08-27 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-07-21